Published in Scand J Gastroenterol on May 01, 1996
Evidence-based clinical practice guidelines for irritable bowel syndrome. J Gastroenterol (2014) 2.30
Irritable bowel syndrome--the main recommendations. Dtsch Arztebl Int (2011) 1.56
Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Gastroenterol Hepatol (2008) 1.52
Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut (2001) 1.43
Diagnosis and management of IBS. Nat Rev Gastroenterol Hepatol (2010) 1.14
Irritable bowel syndrome. Nat Rev Dis Prim (2016) 1.14
Irritable bowel syndrome: a clinical review. World J Gastroenterol (2014) 1.10
An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil (2012) 1.07
Pharmacologic and complementary and alternative medicine therapies for irritable bowel syndrome. Gut Liver (2011) 0.99
Agents that act luminally to treat diarrhoea and constipation. Nat Rev Gastroenterol Hepatol (2012) 0.99
Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol (2003) 0.95
Updates on treatment of irritable bowel syndrome. World J Gastroenterol (2008) 0.94
Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatments. World J Gastroenterol (2014) 0.89
Irritable bowel syndrome. BMJ Clin Evid (2012) 0.87
Diagnosis and treatment of diarrhea-predominant irritable bowel syndrome. Int J Gen Med (2016) 0.86
Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci (2006) 0.85
Centrally acting agents and visceral sensitivity. Gut (2002) 0.85
The treatment of irritable bowel syndrome. Therap Adv Gastroenterol (2009) 0.84
Eluxadoline Efficacy in IBS-D Patients Who Report Prior Loperamide Use. Am J Gastroenterol (2017) 0.81
Current and emergent pharmacologic treatments for irritable bowel syndrome with diarrhea: evidence-based treatment in practice. Therap Adv Gastroenterol (2016) 0.78
Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol (2014) 0.78
An Evidence-based Approach to Therapy in IBS-D: A Case Study Compendium. Gastroenterol Hepatol (N Y) (2010) 0.77
Irritable bowel syndrome: new insights into symptom mechanisms and advances in treatment. F1000Res (2016) 0.77
Irritable bowel syndrome. BMJ Clin Evid (2010) 0.77
Post-Infectious Irritable Bowel Syndrome. Curr Gastroenterol Rep (2017) 0.75
Population-based surveillance by colonoscopy: effect on the incidence of colorectal cancer. Telemark Polyp Study I. Scand J Gastroenterol (1999) 2.89
The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer (1982) 2.85
Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ (1999) 2.44
Irritable bowel syndrome in twins: genes and environment. Gut (2006) 1.81
Design, organization and management of a controlled population screening study for detection of colorectal neoplasia: attendance rates in the NORCCAP study (Norwegian Colorectal Cancer Prevention). Scand J Gastroenterol (2002) 1.68
Growth of colorectal polyps: redetection and evaluation of unresected polyps for a period of three years. Gut (1996) 1.50
Assessment of mucosal inflammation and blood flow in response to four weeks' intervention with probiotics in patients operated with a J-configurated ileal-pouch-anal-anastomosis (IPAA). Scand J Gastroenterol (2004) 1.44
Epidemiological aspects of irritable bowel syndrome in Europe and North America. Digestion (2001) 1.35
Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut (2005) 1.17
Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut (1997) 1.16
Incidence of inflammatory bowel disease in southeastern Norway: evaluation of methods after 1 year of registration. Southeastern Norway IBD Study Group of Gastroenterologists. Digestion (1995) 1.16
The Norwegian guidelines for surveillance after polypectomy: 10-year intervals. Scand J Gastroenterol (1996) 1.15
Epidemiology of polyps in the rectum and colon. Recovery and evaluation of unresected polyps 2 years after detection. Scand J Gastroenterol (1986) 1.15
Does high body fatness increase the risk of presence and growth of colorectal adenomas followed up in situ for 3 years? Am J Gastroenterol (2001) 1.12
Incidence of ulcerative colitis and indeterminate colitis in four counties of southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol (1996) 1.11
Incidence of Crohn's disease in four counties in southeastern Norway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol (1996) 1.09
Screening for colorectal cancer. Lancet (1993) 1.06
Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol (1997) 1.03
Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol (2002) 1.03
Polypectomy of adenomas in the prevention of colorectal cancer: 10 years' follow-up of the Telemark Polyp Study I. A prospective, controlled population study. Scand J Gastroenterol (1996) 1.02
Review: Gastric intrinsic factor secretion. Scand J Gastroenterol (1975) 0.99
Patient tolerance of colonoscopy without sedation during screening examination for colorectal polyps. Gastrointest Endosc (2000) 0.99
Chronic fatigue is associated with impaired health-related quality of life in inflammatory bowel disease. Aliment Pharmacol Ther (2010) 0.96
Do undesirable effects of screening affect all-cause mortality in flexible sigmoidoscopy programmes? Experience from the Telemark Polyp Study 1983-1996. Eur J Cancer Prev (2001) 0.96
Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas? Gut (2003) 0.96
Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol (1999) 0.95
The effect of somatostatin on pentagastrin-stimulated gastric secretion and on plasma gastrin in man. Scand J Gastroenterol (1977) 0.93
Epidemiology of polyps in the rectum and sigmoid colon. Histological examination of resected polyps. Scand J Gastroenterol (1985) 0.93
A small dose of somatostatin inhibits the pentagastrin stimulated gastric secretion of acid, pepsin and intrinsic factor in man. Clin Endocrinol (Oxf) (1978) 0.91
Secondary amyloidosis in inflammatory bowel disease: a study of 18 patients admitted to Rikshospitalet University Hospital, Oslo, from 1962 to 1998. Inflamm Bowel Dis (2001) 0.90
Seasonal variations in the onset of ulcerative colitis. Gut (1996) 0.89
Smoking and colorectal adenomas: a case-control study. Eur J Cancer Prev (2000) 0.89
Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol (2005) 0.89
Relationship between tobacco smoking and colorectal polyps. Scand J Gastroenterol (1987) 0.87
Assessment of mucosal inflammation and circulation in response to probiotics in patients operated with ileal pouch anal anastomosis for ulcerative colitis. Scand J Gastroenterol (2003) 0.86
The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann Rheum Dis (2007) 0.85
CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer. Genes Immun (2011) 0.85
Detection of cancer-related proteins by two-dimensional electrophoresis. Ann N Y Acad Sci (1984) 0.84
The effect of carbachol and pentagastrin on the gastric secretion of acid pepsin, and intrinsic factor (IF) in man. Scand J Gastroenterol (1975) 0.84
No association between the TUCAN (CARD8) Cys10Stop mutation and inflammatory bowel disease in a large retrospective German and a clinically well-characterized Norwegian sample. Gastroenterology (2007) 0.83
Secretory component mRNA and protein expression in colorectal adenomas and carcinomas. Br J Cancer (1996) 0.83
Computed tomography and ultrasound of the normal pancreas. Acta Radiol Diagn (Stockh) (1982) 0.82
Dietary factors and colorectal polyps: a case-control study. Eur J Cancer Prev (1995) 0.82
Lifestyle-related factors and colorectal polyps: preliminary results from a Norwegian follow-up and intervention study. Eur J Cancer Prev (2002) 0.81
The distribution of polyps in the large intestine. Ann Gastroenterol Hepatol (Paris) (1986) 0.80
The relationship between faecal bile acid profile with or without supplementation with calcium and antioxidants on recurrence and growth of colorectal polyps. Eur J Cancer Prev (1998) 0.79
The effect of duodenal juice on the intrinsic factor (IF) activity in gastric juice. Scand J Gastroenterol (1975) 0.79
Distribution of dysplasia in ulcerative colitis. Scand J Gastroenterol (1984) 0.79
Does intake of alcohol increase the risk of presence and growth of colorectal adenomas followed-up in situ for three years? Scand J Gastroenterol (2002) 0.78
The effect of atropine and vagotomy on the secretion of gastric intrinsic factor (IF) in man. Scand J Gastroenterol (1975) 0.78
Colonic adenoma: natural history. Dig Dis (1991) 0.78
The effect of exogenous secretin and cholecystokinin (CCK) on pentagastrin-stimulated intrinsic factor (IF) secretion in man. Scand J Gastroenterol (1974) 0.77
Results from two repeated 5 day dietary records with a 1 y interval among patients with colorectal polyps. Eur J Clin Nutr (2001) 0.77
Enzyme activity and protein patterns as premalignant markers in mucosal biopsy specimens from the large intestine. Scand J Gastroenterol Suppl (1985) 0.76
Clinical and economic outcomes in a population-based European cohort of 948 ulcerative colitis and Crohn's disease patients by Markov analysis. Aliment Pharmacol Ther (2009) 0.76
Enzymatic characteristics of tubular adenomas and carcinomas of the large intestine. Gut (1982) 0.75
The effect of attending a flexible sigmoidoscopic screening program on the prevalence of colorectal adenomas at 13-year follow-up. Am J Gastroenterol (2001) 0.75
Diagnostic value of gastrointestinal endoscopy in patients with uncharacteristic abdominal disorders. Scand J Gastroenterol (1985) 0.75
Effect of atropine on insulin-stimulated gastrin release and gastric secretion of acid, pepsin, and intrinsic factor (IF). Scand J Gastroenterol (1974) 0.75
Duodenal ulcer treated with omeprazole: healing and relapse rates. Does treatment duration influence subsequent remission? Scand J Gastroenterol (1989) 0.75
[Non-ulcer dyspepsia. Classification and differentiation from organic disease]. Tidsskr Nor Laegeforen (1989) 0.75
The effect of somatostatin on gastrin release and gastric secretion. Scand J Gastroenterol Suppl (1976) 0.75
Lactate dehydrogenase isoenzymes in mucosal biopsy specimens from patients with ulcerative colitis. Scand J Gastroenterol (1985) 0.75
The effect of graded doses of pentagastrin and secretin on the intrinsic factor (IF) secretion in man. Scand J Gastroenterol (1974) 0.75
[Comparison of lactose absorption, lactase activity and histological changes in blind biopsies from the small intestine]. Tidsskr Nor Laegeforen (1977) 0.75
Abdominal ultrasonography in patients with uncharacteristic abdominal symptoms. Scand J Gastroenterol (1983) 0.75
Drinking water and the prevalence of colorectal adenomas: an epidemiologic study in Telemark, Norway. Eur J Cancer Prev (1992) 0.75
[Ulcerative colitis]. Tidsskr Nor Laegeforen (2001) 0.75
Interferon-alpha 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study. Scand J Gastroenterol (1995) 0.75
[Sick of food? Knowledge and hypothesis on food intolerance]. Nord Med (1996) 0.75
A prospective study of patients with uncharacteristic abdominal disorders. Scand J Gastroenterol (1985) 0.75
The effect of atropine on insulin stimulated gastric secretion and gastrin release. Mater Med Pol (1977) 0.75
[New diagnostic possibilities in colorectal hemorrhage]. Tidsskr Nor Laegeforen (1982) 0.75
The effect of calcium and pentagastrin on the gastric secretion of acid, pepsin, and intrinsic factor (IF) in man. Scand J Gastroenterol (1974) 0.75
Relation between food provocation and systemic immune activation in patients with food intolerance. Lancet (2000) 0.75
[Abdominal complaints of unknown origin. A prospective study]. Tidsskr Nor Laegeforen (1986) 0.75
A double-blind crossover study of the effect of a chromone carboxylic acid, FPL 52694, on overnight fasting gastric acid secretion. Scand J Gastroenterol (1986) 0.75
Haemoglobin-coated charcoal for estimation of gastric intrinsic factor. Scand J Gastroenterol (1973) 0.75
Measurement of enzyme activity in colonic biopsies: a test for premalignancy in ulcerative colitis? Scand J Gastroenterol (1984) 0.75
The rate of healing of duodenal ulcers during omeprazole treatment. Scand J Gastroenterol (1985) 0.75
Two-dimensional electrophoretic patterns of proteins of normal mucosa, polyps, and carcinomas of the large intestine. Clin Chem (1982) 0.75
Computer tomography of the abdomen in patients with uncharacteristic abdominal disturbances. Scand J Gastroenterol (1983) 0.75
[Should ulcer treatment be aimed against Helicobacter pylori?]. Tidsskr Nor Laegeforen (1991) 0.75
[Campylobacter colitis]. Tidsskr Nor Laegeforen (1980) 0.75
The CARD15 gene mutation in Crohn disease. Scand J Gastroenterol (2003) 0.75
The effect of pentagastrin, exogenous secretin, and cholecystokinin (CCK) on the intrinsic factor (IF) secretion in man. Scand J Gastroenterol Suppl (1974) 0.75
Epidemiology of polyps in the rectum and sigmoid colon. Size, enzyme levels, DNA distributions, and nuclear diameter in polyps of the large intestine. Scand J Gastroenterol (1985) 0.75
[Radiation injury of the intestine]. Tidsskr Nor Laegeforen (1989) 0.75
Gastric secretory response to different doses of carbachol and pentagastrin in man. Scand J Gastroenterol (1976) 0.75
Patient compliance with intensive antacid treatment. A multi-centre study. Hepatogastroenterology (1986) 0.75
Effect of cimetidine on intrinsic factor secretion stimulated by different doses of pentagastrin in patients with impaired renal function. Scand J Gastroenterol (1983) 0.75
Somatostatin inhibits insulin-stimulated gastrin release and gastric secretion of acid, pepsin, and intrinsic factor (IF) in duodenal ulcer patients. Scand J Gastroenterol (1976) 0.75